Cargando…
Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study
OBJECTIVE: Endocervical adenocarcinomas (ECA) and endometrial adenocarcinomas (EMA) are uterine malignancies that have differing biological behaviors. The choice of an appropriate therapeutic plan rests on the tumor's site of origin. In this study, we propose to evaluate whether PR adds value t...
Autores principales: | Liao, Chiung-Ling, Lee, Ming-Yung, Tyan, Yeu-Sheng, Kok, Lai-Fong, Wu, Tina S, Koo, Chiew-Loon, Wang, Po-Hui, Chao, Kuan-Chong, Han, Chih-Ping |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694169/ https://www.ncbi.nlm.nih.gov/pubmed/19476621 http://dx.doi.org/10.1186/1479-5876-7-37 |
Ejemplares similares
-
Scoring mechanisms of p16(INK4a )immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study
por: Koo, Chiew-Loon, et al.
Publicado: (2009) -
Analysis of Cytosol CA15‐3, Carcinoembryonic Antigen, Estrogen and Progesterone Receptors in Breast Cancer Tissues
por: Miya, Toshimichi, et al.
Publicado: (1992) -
Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach
por: Dekker, T. J. A., et al.
Publicado: (2015) -
Erratum to: Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach
por: Dekker, T. J. A., et al.
Publicado: (2015) -
Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer
por: Wang, Caifeng, et al.
Publicado: (2020)